Freedom Investment Management Inc. Trims Position in ADMA Biologics Inc $ADMA

Freedom Investment Management Inc. decreased its position in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 14.2% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 13,107 shares of the biotechnology company’s stock after selling 2,172 shares during the period. Freedom Investment Management Inc.’s holdings in ADMA Biologics were worth $239,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Invesco Ltd. lifted its stake in shares of ADMA Biologics by 13.9% during the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock valued at $255,279,000 after buying an additional 1,570,649 shares during the period. Nuveen LLC purchased a new position in shares of ADMA Biologics during the first quarter valued at approximately $93,543,000. American Century Companies Inc. lifted its stake in shares of ADMA Biologics by 12.7% during the first quarter. American Century Companies Inc. now owns 4,252,362 shares of the biotechnology company’s stock valued at $84,367,000 after buying an additional 478,800 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of ADMA Biologics by 8.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 3,320,251 shares of the biotechnology company’s stock valued at $59,366,000 after buying an additional 271,305 shares during the period. Finally, Driehaus Capital Management LLC lifted its stake in shares of ADMA Biologics by 114.9% during the first quarter. Driehaus Capital Management LLC now owns 2,946,570 shares of the biotechnology company’s stock valued at $58,460,000 after buying an additional 1,575,363 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $27.67.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $15.60 on Tuesday. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. The company has a market cap of $3.72 billion, a P/E ratio of 18.14 and a beta of 0.47. ADMA Biologics Inc has a fifty-two week low of $13.50 and a fifty-two week high of $25.67. The firm’s 50 day moving average is $15.77 and its two-hundred day moving average is $18.21.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.01. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The company had revenue of $121.98 million during the quarter, compared to analyst estimates of $121.77 million. During the same quarter in the prior year, the business earned $0.13 earnings per share. The business’s quarterly revenue was up 13.8% compared to the same quarter last year. Analysts expect that ADMA Biologics Inc will post 0.51 EPS for the current year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.